Ionis Pharmaceuticals, Inc. (IONS)
| Market Cap | 13.41B |
| Revenue (ttm) | 944.00M |
| Net Income (ttm) | -381.00M |
| Shares Out | 165.19M |
| EPS (ttm) | -2.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,781,245 |
| Open | 80.59 |
| Previous Close | 80.60 |
| Day's Range | 80.06 - 82.10 |
| 52-Week Range | 23.95 - 86.74 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 85.73 (+5.64%) |
| Earnings Date | Feb 25, 2026 |
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $944.00 million, an increase of 33.87% compared to the previous year's $705.14 million. Losses were -$381.00 million, -16.06% less than in 2024.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $85.73, which is an increase of 5.64% from the latest price.
News
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for heredi...
Ionis Pharmaceuticals: Digesting Recent Events
Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 b...
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Dru...
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript
Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) on Wednesday reported a fourth quarter adjusted loss of $1.15, better than the Wall Street loss estimate of $1.32
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the fourth quarter and year ended December 3...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th...
Ionis updates time for fourth quarter and full year 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live w...
Ionis to hold fourth quarter and full year 2025 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourt...
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (don...
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
Ionis Pharmaceuticals (IONS) has appreciated ~25% since my last upgrade, reflecting strong momentum. This article spotlights Olezarsen, Ionis's wholly owned molecule, as a key driver of future upside....
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected...
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol...
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safet...
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J....
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zilganers...
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen...
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants A...
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN...
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP...
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. ( IONS) Stifel 2025 Healthcare Conference November 13, 2025 8:00 AM EST Company Participants Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Elizabeth L....
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “...
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate princip...